- Home>
- Journal Watch
- >
- pegylated interferon
Search for pegylated interferon in all Journal Watch editions
Physician-authored summaries on the latest research on pegylated interferon, editorials on pegylated interferon, and perspectives on pegylated interferon - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 131 results - Relevance
- Date
You searched for: pegylated interferon
-
Pegylated Interferon-Lambda for Chronic Hepatitis C Virus Infection
- December 22, 2010
- David A. Johnson, MD
- Gastroenterology
In a phase Ib study, PEG-IFN-λ showed promise in both treatment-naive and relapsing patients.- Reviewing:
- Muir AJ et al., Hepatology 2010 Sep; 52:822.
-
Predicting Treatment Success for Hepatitis C Among HIV-Infected Patients
- October 20, 2010
- Neil M. Ampel, MD
- Infectious Diseases
The rs12979860 CC genotype was associated with an increased likelihood of sustained viral response after pegylated interferon alfa-2/ribavirin treatment.- Reviewing:
- Pineda JA et al., Clin Infect Dis 2010 Oct 1; 51:788.
-
Pegylated Interferon Alfa for Acute Hepatitis C
- September 15, 2010
- Neil M. Ampel, MD
- Infectious Diseases
Pegylated interferon alfa-2a at 135 µg weekly for 24 weeks cleared hepatitis C viremia in 89% of hemodialysis patients with acute infection.- Reviewing:
- Liu C-H et al., Clin Infect Dis 2010 Sep 1; 51:541.
-
Rituximab for Mixed Cryoglobulinemia
- August 24, 2010
- David Green, MD, PhD
- Oncology and Hematology
The combination of rituximab with pegylated interferon and ribavirin boosted responses in MC patients with hepatitis C virus infection.- Reviewing:
- Saadoun D et al., Blood 2010 Jul 22; 116:326. Dammacco F et al., Blood 2010 Jul 22; 116:343. Petrarca A et al., Blood 2010 Jul 22; 116:335.
-
Consensus Interferon After Nonresponse to Standard HCV Therapy
- August 28, 2009
- Atif Zaman, MD, MPH
- Gastroenterology
Patients without cirrhosis who demonstrated some sensitivity to pegylated interferon achieved the best response to interferon alfacon-1 plus ribavirin.- Reviewing:
- Bacon BR et al., Hepatology 2009 Jun; 49:1838.
-
Predicting Response to Hepatitis B Virus Therapy
- August 7, 2009
- Atif Zaman, MD, MPH
- Gastroenterology
Hepatitis B virus surface antigen levels during and after pegylated interferon alfa-2a therapy might be predictors of sustained virologic response.- Reviewing:
- Moucari R et al., Hepatology 2009 Apr; 49:1151. Brunetto MR et al., Hepatology 2009 Apr; 49:1141.
-
Interferon for Polycythemia Vera
- November 10, 2008
- David Green, MD, PhD
- Oncology and Hematology
All patients achieved hematologic response after 1 year.- Reviewing:
- Kiladjian J-J et al., Blood 2008 Oct 15; 112:3065.
-
Baseline CD4-Cell Count and HCV Treatment Success
- January 14, 2008
- Helmut Albrecht, MD
- HIV/AIDS
Retrospective analyses in HIV/HCV-coinfected patients did not demonstrate a link between baseline CD4-cell count and HCV treatment response, but the total number of patients with low CD4-cell counts was too small to make this conclusion definitively.- Reviewing:
- Opravil M et al., J Acquir Immune Defic Syndr 2008 Jan 1; 47:36. Valerio L et al., J Acquir Immune Defic Syndr 2008 Jan 1; 47:50.
-
The Predictive Value of Rapid Virologic Response to HCV Therapy in Coinfected Patients
- July 23, 2007
- Sonia Nagy Chimienti, MD
- HIV/AIDS
Retrospective data indicate that, in coinfected patients, rapid virologic response to HCV therapy might predict sustained virologic response.- Reviewing:
- Mira JA et al., Antivir Ther 2007; 12:523-9.
-
Risk Factors for HCV Relapse in HIV-Infected Patients
- July 9, 2007
- Rajesh T. Gandhi, MD
- HIV/AIDS
Independent predictors of relapse after HCV treatment in 256 patients included high pretreatment HCV RNA levels and detectable HCV RNA 4 weeks after therapy initiation.- Reviewing:
- Núñez M et al., J Acquir Immune Defic Syndr 2007 Apr 26;:
-
Treating Acute HCV in HIV-Coinfected Patients
- February 12, 2007
- Carlos del Rio, MD
- HIV/AIDS
In a small trial, more than 60% of patients achieved a sustained virologic response when HCV infection was treated during the acute phase.- Reviewing:
- Vogel M et al., Antivir Ther 2006; 11:1097-101.
-
Think “Acute HCV”— Early Treatment May Be Better
- June 28, 2006
- Camilla S. Graham, MD, MPH
- HIV/AIDS
A small study adds support for the treatment of acute HCV infection in HIV-coinfected patients.- Reviewing:
- Dominguez S et al., AIDS 2006 May 12; 20:1157-61.
-
Some Patients with Persistent HCV Infection Respond to Retreatment with Pegylated Interferon
- December 13, 2005
- Atif Zaman, MD, MPH
- Gastroenterology
Patients who don’t respond to, or relapse after, IFN monotherapy have a reasonable chance of viral clearance with peginterferon plus ribavirin.- Reviewing:
- Jacobson IM et al., Am J Gastroenterol 2005 Nov; 100:2453-62.
-
Treatment of Acute HCV Infection
- October 26, 2005
- Helmut Albrecht, MD
- HIV/AIDS
Treatment with pegylated interferon plus ribavirin for 24 weeks resulted in a sustained virologic response in 59% of HIV-positive patients with acute HCV infection.- Reviewing:
- Gilleece YC et al., J Acquir Immune Defic Syndr 2005 Sep 1; 40:41-6.
-
HCV Treatment — On the Threshold
- April 1, 2013
- Paul E. Sax, MD
- HIV/AIDS
Interferon-free regimens stole the show. -
Escitalopram Associated with Less Interferon-Induced Depression in Hepatitis C Free
- July 17, 2012
- Physician's First Watch
Depression, a relatively common side effect of pegylated interferon in treating hepatitis C, is less frequent when interferon is taken with an antidepressant, according to... -
Hepatitis C Virus and HIV Coinfection: Translating New Discoveries into Clinical Practice
- March 15, 2010
- Rajesh T. Gandhi, MD
- HIV/AIDS
The 2010 Retrovirus Conference enhanced our understanding of the biology, clearance, and treatment of hepatitis C virus infection. -
HCV Sequence Variation Predicts Response to Therapy
- January 14, 2009
- Rajesh T. Gandhi, MD
- Infectious Diseases
Using HCV markers to forecast treatment outcome could lead to a personalized approach to management.- Reviewing:
- Aurora R et al., J Clin Invest 2009 Jan 5; 119:225. Oh TS and Rice CM., J Clin Invest 2009 Jan 5; 119:5.
-
Peginterferon and Ribavirin for Difficult-to-Treat HCV: Is More Better?
- December 12, 2008
- Atif Zaman, MD, MPH
- Gastroenterology
Data from a pilot study suggest that higher doses of peginterferon and ribavirin for chronic HCV infection leads to lower relapse rates in difficult-to-treat cases.- Reviewing:
- Fried MW et al., Hepatology 2008 Oct; 48:1033.
-
Top Oncology and Hematology Stories: 2008 Free
- December 9, 2008
- The Editors
- Oncology and Hematology
A perspective on the most important research in the field from the past year
Sort by:
Items 1 to 20 of 131 results - Relevance
- Date
